ANZCTR search results

The aim of the study is to determine whether the use of the drug Pregabalin can reduce or eliminate phantom pain after leg amputations

The purpose of the study is to evaluate the effect of tetrahydrobiopterin (BH4) on myocardial blood flow and vascular function in patients with coronary artery disease.

Dementia Care Mapping (DCM) employs detailed observations of persons with dementia to identify factors which promote their well-being and ill-being. This provides the basis for health service delivery which is person-centred and focused on the resident's well-being. Consequently, the persons' behavioural disturbance will reduce. This is a randominsed control study conducted over 2 years with 360 persons with dementia , with 200 care staff in 15 matched residential dementia care units in a prepost test, followup design.

The objective of the trial is to compare the efficacy (based on time to progression of tumour) and tolerance of Hepatic Intra-Arterial injection of Doxorubicin Transdrug® every 4 weeks, up to 3 courses with control standard treatment according to each centre’s usual practice (including TACE). This is an open label, multicentre, randomized in two parallel groups, Phase 2-3 study. The trial is designed to be performed in two successive parts, Phase 2 and Phase 3. At the end of the Phase 2, the efficacy of Doxorubicin Transdrug® will be evaluated based on the rate of patient free of local progression 3 months after randomisation. If more than 66% of patients treated with Doxorubicin Transdrug® are free of local progression, the study will be pursued and patients included in the Phase 2 study will automatically be followed and analyzed in the Phase 3 study. A total of 200 patients will be accrued of whom 50 patients will be accrued for the Phase 2. Patients satisfying inclusion and exclusion criteria will be centrally randomised to one of two treatments groups. Group A: Patients will receive a course of hepatic intra-arterial Doxorubicin Transdrug® on Day1. The treatment will be repeated every 4 weeks or until D90 (i.e. 3 months after randomization) for a total of 3 courses in the absence of disease progression or unacceptable toxicity. Group B: Patients will receive treatment according to each centre’s usual practice (including TACE), treatment will be repeated until D90 (i.e. 3 months after randomization) in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for one year.

The primary purpose of the study was to evaluate the effectiveness of a program that aimed to build coping skills for adolescents who were being bullied at school. We predicted that adolecents who completed the program would reported less bullying, reduced impact of being bullied, and lower symptoms of anxiety and depression than adolescents who had been allocated to a wait-list control condition.

The study is a double blind, placebo controlled, randomised trial to be conducted over 6 weeks in parallel groups of otherwise healthy individuals. The study will compare baseline in vivo and ex vivo changes of antioxidant levels and various immune cell functions with end of study outcomes.

The objective of this trial was specifically aimed at answering the research question: For the general cataract population, does the use of partial coherence interferometry improve postoperative outcomes compared with current generation applanation ultrasound biometry, as measured by postoperative refractive error, by increasing the accuracy of calculation of the intraocular lens power.

Non-valvular atrial fibrillation (NVAF) is a common heart condition associated with a major risk of fatal and disabling stroke. Inexpensive anticoagulant medication has been proven to reduce all-cases of death and stroke in people with NVAF. Anticoagulant treatment for NVAF is substantially underused resulting in avoidable patient deaths and disabling stroke. This study seeks to optimise the management of NVAF in general practice. We are developing an educational program for general practitioners which we hypothesis will increase the number of people with NVAF over the age of 65 who are prescribed anticoagulant medication.

The question is whether a health broker being involved in the care of a child with otitis media can improve the care of that child. This will be measured by seeing whether children with access to a health broker follow the doctor's care plan more closely than children without a health broker

A prospective multi-center, non-randomized, single arm trial enrolling up to 60 patients with symptomatic ischemic heart disease attributable to a bifurcation lesion that is amenable to percutaneous treatment with stenting. A bifurcation lesion must have =/> 50% stenosis in the main branch. Trial patients may have multiple vessel disease but only a single bifurcation lesion per patient mmay be treated during the trial procedure, with no other lesions of any type treated at this time-point. Clinical follow-up assessment will be performed at 30-days post procedure. Patient contact for follow-up assesment will be performed at 6 months, 9 months and 12 months post-procedure